Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Le Palais des Congrès

Apr 13, 2015 9:00 AM - Apr 15, 2015 5:30 PM

2, Place de la porte Maillot, F-75017 Paris, France

27th Annual EuroMeeting

PHARMA MEDICAL AFFAIRS: VISION THROUGH 2020

Session Chair(s)

Gustavo  Kesselring, MD

Gustavo Kesselring, MD

Senior Visiting Lecturer

KING´S COLLEGE LONDON, Brazil

Medical affairs organisations have emerged over the past half century in response to federal regulations around the separation of medical and commercial activities within drug companies. Many companies also chose to focus R&D resources on developing new products and moved post-launch activities, such as finding new indications for existing drugs, into the medical affairs function. Continued pressure from regulatory agencies and public sentiment have pushed more and more activities into Medical affairs organisations. Today, these organisations commonly involve the following medical activities: Medical education, medical field teams, post-launch clinical trials, medical-information services, medical communications, medical strategic activities and health economics and outcome research activities. The vision from medical departments of three global pharmaceutical companies will be addressed and balanced with the vision of the Standing Committee of the European Doctors (CPME).

Speaker(s)

Michael  Devoy

Panel Discussion

Michael Devoy

Bayer AG, Germany

Jacques  de Haller

Panel Discussion

Jacques de Haller

Standing Committee Of European Doctors, Switzerland

Vice President

Michael  Rosenblatt, MD

Panel Discussion

Michael Rosenblatt, MD

Flagship Pioneering, United States

Chief Medical Officer

Tamas  Suto

Panel Discussion

Tamas Suto

Sanofi, France

Head of Medical Excellence

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.